India to United Kingdom: Paracetamol Export Trade Route

To import finished pharmaceutical formulations containing Paracetamol into the United Kingdom, Indian exporters must comply with the Medicines and Healthcare products Regulatory Agency (MHRA) requirements. A Marketing Authorisation (MA) is mandatory for all medicines placed on the UK market. The application process involves submitting a comprehensive dossier, typically in the Common Technical Document (CTD) format, which includes detailed information on the product's quality, safety, and efficacy. The processing time for new applications is approximately 60 working days, excluding any additional time required for supplementary information. Fees are applicable and vary based on the number of sites involved in the application. Additionally, Good Manufacturing Practice (GMP) inspections of the manufacturing facilities are conducted to ensure compliance with UK standards. These inspections assess the manufacturing processes, quality control measures, and overall facility conditions. The timelines for inspections are coordinated with the application process, and any deficiencies identified may require corrective actions before approval. It is essential for Indian manufacturers to ensure that their facilities meet the MHRA's GMP standards to facilitate a smooth importation process. (gov.uk)

Indian exporters aiming to supply finished Paracetamol formulations to the United Kingdom must possess GMP certifications recognized by the MHRA. These certifications confirm that the manufacturing processes adhere to the required quality standards. The MHRA maintains a list of GMP-compliant manufacturers, which is accessible through their official portal. For instance, Reckitt Benckiser Healthcare International Limited holds registration number UK API 12862, indicating compliance with MHRA standards. Regular inspections are conducted to ensure ongoing compliance, and any deviations may result in corrective actions or suspension of certification. Maintaining up-to-date GMP certifications is crucial for sustaining trade relations and ensuring product acceptance in the UK market. (cms.mhra.gov.uk)

In the past 18 months, the MHRA has implemented several regulatory changes affecting the importation of pharmaceutical products, including those from India. Notably, from 1 January 2022, a UK Manufacturing and Import Authorisation (MIA(IMP)) is required to verify that Investigational Medicinal Products (IMPs) imported from approved countries have been certified by a Qualified Person (QP) in the exporting country. This oversight process ensures that imported IMPs meet UK standards without the need for recertification. Additionally, the MHRA has updated its guidelines on the importation of unlicensed medicines, emphasizing the need for importers to notify the agency of their intent to import and provide supporting documentation for assessment. These developments aim to enhance the safety and quality of medicinal products entering the UK market. (gov.uk)

MARKET

The United Kingdom's Paracetamol market was valued at approximately USD 19.25 million in 2024 and is projected to reach USD 26.73 million by 2035, growing at a compound annual growth rate (CAGR) of around 3.03% from 2025 to 2035. This growth is driven by factors such as the prevalence of conditions like headaches, osteoarthritis, and other pain-related disorders, which contribute to sustained demand for Paracetamol-based products. Healthcare spending in the UK has been on an upward trajectory, further supporting the market's expansion. The aging population also plays a significant role, as older adults are more susceptible to conditions requiring pain management. The UK relies on both domestic production and imports to meet Paracetamol demand, with imports supplementing domestic production to ensure a consistent supply.

Finished pharmaceutical formulations containing Paracetamol (HS Code 30049069) imported into the United Kingdom are subject to an MFN (Most Favored Nation) import duty of 0%. This indicates that no standard import duty is levied on these products. Value Added Tax (VAT) is applicable at the standard rate of 20% on the total value of the goods, including shipping and insurance costs. There are no preferential rates or Free Trade Agreement (FTA) benefits currently applicable to these imports. Additionally, no anti-dumping duties have been imposed on Paracetamol formulations from India. Importers should also be aware of potential additional charges, such as customs clearance fees and handling charges, which may vary depending on the logistics provider and specific import conditions.

India is a significant supplier of finished Paracetamol formulations to the United Kingdom, holding a substantial share of the market. Other countries exporting Paracetamol formulations to the UK include China and various European Union (EU) member states. India's pricing is generally competitive, often offering cost advantages over Chinese and EU suppliers. The quality of Indian Paracetamol formulations is recognized and accepted by UK regulatory authorities, provided that manufacturers comply with GMP standards. Supply reliability is also a key factor, with Indian exporters maintaining consistent delivery schedules and meeting the UK's demand for Paracetamol products.

CORRIDOR

As of March 2026, the India-United Kingdom pharmaceutical corridor remains robust, with no significant disruptions reported in shipping routes or freight rates. Sea freight from India to the UK typically takes between 25 to 30 days, while air freight is completed in approximately 7 to 10 days. The majority of shipments are transported by sea, accounting for about 85% of the total, with air freight comprising the remaining 15%. Currency trends have remained stable, with the Indian Rupee and British Pound maintaining consistent exchange rates, facilitating predictable pricing for transactions. Importers and exporters continue to monitor global shipping conditions to anticipate and mitigate any potential disruptions.

Recent geopolitical developments have had minimal impact on the India-United Kingdom pharmaceutical trade corridor. There are no current sanctions or trade restrictions affecting the importation of Paracetamol formulations from India to the UK. Global conflicts have not significantly disrupted shipping routes or increased insurance premiums for these shipments. Both Indian and UK authorities continue to engage in diplomatic efforts to ensure the uninterrupted flow of pharmaceutical products, including Paracetamol formulations.

There is no existing Free Trade Agreement (FTA) between India and the United Kingdom specifically covering pharmaceutical products. Both countries are members of the World Trade Organization (WTO) and adhere to its regulations governing international trade. Bilateral meetings and trade facilitation measures are periodically conducted to discuss and enhance trade relations, including the importation of pharmaceutical products. These discussions focus on streamlining customs procedures, ensuring compliance with regulatory standards, and addressing any trade barriers that may arise.

The landed cost for importing finished Paracetamol formulations from India to the United Kingdom includes several components:

• FOB (Free On Board) Price: The cost of the goods at the port of departure in India.
• Freight Charges: Costs associated with transporting the goods from India to the UK, varying based on shipping method (sea or air).
• Insurance: Coverage for potential risks during transit.
• Customs Duty: 0% import duty for HS Code 30049069.
• Customs Clearance Fees: Charges for processing the goods through UK customs.

To import finished pharmaceutical formulations containing Paracetamol into the United Kingdom, Indian exporters must comply with the Medicines and Healthcare products Regulatory Agency (MHRA) requirements. A Marketing Authorisation (MA) is mandatory for all medicines placed on the UK market. The application process involves submitting a comprehensive dossier, typically in the Common Technical Document (CTD) format, which includes detailed information on the product's quality, safety, and efficacy. The processing time for new applications is approximately 60 working days, excluding any additional time required for supplementary information. Fees are applicable and vary based on the number of sites involved in the application. Additionally, Good Manufacturing Practice (GMP) inspections of the manufacturing facilities are conducted to ensure compliance with UK standards. These inspections assess the manufacturing processes, quality control measures, and overall facility conditions. The timelines for inspections are coordinated with the application process, and any deficiencies identified may require corrective actions before approval. It is essential for Indian manufacturers to ensure that their facilities meet the MHRA's GMP standards to facilitate a smooth importation process. (gov.uk)

Indian exporters aiming to supply finished Paracetamol formulations to the United Kingdom must possess GMP certifications recognized by the MHRA. These certifications confirm that the manufacturing processes adhere to the required quality standards. The MHRA maintains a list of GMP-compliant manufacturers, which is accessible through their official portal. For instance, Reckitt Benckiser Healthcare International Limited holds registration number UK API 12862, indicating compliance with MHRA standards. Regular inspections are conducted to ensure ongoing compliance, and any deviations may result in corrective actions or suspension of certification. Maintaining up-to-date GMP certifications is crucial for sustaining trade relations and ensuring product acceptance in the UK market. (cms.mhra.gov.uk)

In the past 18 months, the MHRA has implemented several regulatory changes affecting the importation of pharmaceutical products, including those from India. Notably, from 1 January 2022, a UK Manufacturing and Import Authorisation (MIA(IMP)) is required to verify that Investigational Medicinal Products (IMPs) imported from approved countries have been certified by a Qualified Person (QP) in the exporting country. This oversight process ensures that imported IMPs meet UK standards without the need for recertification. Additionally, the MHRA has updated its guidelines on the importation of unlicensed medicines, emphasizing the need for importers to notify the agency of their intent to import and provide supporting documentation for assessment. These developments aim to enhance the safety and quality of medicinal products entering the UK market. (gov.uk)

MARKET

The United Kingdom's Paracetamol market was valued at approximately USD 19.25 million in 2024 and is projected to reach USD 26.73 million by 2035, growing at a compound annual growth rate (CAGR) of around 3.03% from 2025 to 2035. This growth is driven by factors such as the prevalence of conditions like headaches, osteoarthritis, and other pain-related disorders, which contribute to sustained demand for Paracetamol-based products. Healthcare spending in the UK has been on an upward trajectory, further supporting the market's expansion. The aging population also plays a significant role, as older adults are more susceptible to conditions requiring pain management. The UK relies on both domestic production and imports to meet Paracetamol demand, with imports supplementing domestic production to ensure a consistent supply.

Finished pharmaceutical formulations containing Paracetamol (HS Code 30049069) imported into the United Kingdom are subject to an MFN (Most Favored Nation) import duty of 0%. This indicates that no standard import duty is levied on these products. Value Added Tax (VAT) is applicable at the standard rate of 20% on the total value of the goods, including shipping and insurance costs. There are no preferential rates or Free Trade Agreement (FTA) benefits currently applicable to these imports. Additionally, no anti-dumping duties have been imposed on Paracetamol formulations from India. Importers should also be aware of potential additional charges, such as customs clearance fees and handling charges, which may vary depending on the logistics provider and specific import conditions.

India is a significant supplier of finished Paracetamol formulations to the United Kingdom, holding a substantial share of the market. Other countries exporting Paracetamol formulations to the UK include China and various European Union (EU) member states. India's pricing is generally competitive, often offering cost advantages over Chinese and EU suppliers. The quality of Indian Paracetamol formulations is recognized and accepted by UK regulatory authorities, provided that manufacturers comply with GMP standards. Supply reliability is also a key factor, with Indian exporters maintaining consistent delivery schedules and meeting the UK's demand for Paracetamol products.

CORRIDOR

As of March 2026, the India-United Kingdom pharmaceutical corridor remains robust, with no significant disruptions reported in shipping routes or freight rates. Sea freight from India to the UK typically takes between 25 to 30 days, while air freight is completed in approximately 7 to 10 days. The majority of shipments are transported by sea, accounting for about 85% of the total, with air freight comprising the remaining 15%. Currency trends have remained stable, with the Indian Rupee and British Pound maintaining consistent exchange rates, facilitating predictable pricing for transactions. Importers and exporters continue to monitor global shipping conditions to anticipate and mitigate any potential disruptions.

Recent geopolitical developments have had minimal impact on the India-United Kingdom pharmaceutical trade corridor. There are no current sanctions or trade restrictions affecting the importation of Paracetamol formulations from India to the UK. Global conflicts have not significantly disrupted shipping routes or increased insurance premiums for these shipments. Both Indian and UK authorities continue to engage in diplomatic efforts to ensure the uninterrupted flow of pharmaceutical products, including Paracetamol formulations.

There is no existing Free Trade Agreement (FTA) between India and the United Kingdom specifically covering pharmaceutical products. Both countries are members of the World Trade Organization (WTO) and adhere to its regulations governing international trade. Bilateral meetings and trade facilitation measures are periodically conducted to discuss and enhance trade relations, including the importation of pharmaceutical products. These discussions focus on streamlining customs procedures, ensuring compliance with regulatory standards, and addressing any trade barriers that may arise.

The landed cost for importing finished Paracetamol formulations from India to the United Kingdom includes several components:

• FOB (Free On Board) Price: The cost of the goods at the port of departure in India.
• Freight Charges: Costs associated with transporting the goods from India to the UK, varying based on shipping method (sea or air).
• Insurance: Coverage for potential risks during transit.
• Customs Duty: 0% import duty for HS Code 30049069.
• Customs Clearance Fees: Charges for processing the goods through UK customs.

To import finished pharmaceutical formulations containing Paracetamol into the United Kingdom, Indian exporters must comply with the Medicines and Healthcare products Regulatory Agency (MHRA) requirements. A Marketing Authorisation (MA) is mandatory for all medicines placed on the UK market. The application process involves submitting a comprehensive dossier, typically in the Common Technical Document (CTD) format, which includes detailed information on the product's quality, safety, and efficacy. The processing time for new applications is approximately 60 working days, excluding any additional time required for supplementary information. Fees are applicable and vary based on the number of sites involved in the application. Additionally, Good Manufacturing Practice (GMP) inspections of the manufacturing facilities are conducted to ensure compliance with UK standards. These inspections assess the manufacturing processes, quality control measures, and overall facility conditions. The timelines for inspections are coordinated with the application process, and any deficiencies identified may require corrective actions before approval. It is essential for Indian manufacturers to ensure that their facilities meet the MHRA's GMP standards to facilitate a smooth importation process. (gov.uk)

Indian exporters aiming to supply finished Paracetamol formulations to the United Kingdom must possess GMP certifications recognized by the MHRA. These certifications confirm that the manufacturing processes adhere to the required quality standards. The MHRA maintains a list of GMP-compliant manufacturers, which is accessible through their official portal. For instance, Reckitt Benckiser Healthcare International Limited holds registration number UK API 12862, indicating compliance with MHRA standards. Regular inspections are conducted to ensure ongoing compliance, and any deviations may result in corrective actions or suspension of certification. Maintaining up-to-date GMP certifications is crucial for sustaining trade relations and ensuring product acceptance in the UK market. (cms.mhra.gov.uk)

In the past 18 months, the MHRA has implemented several regulatory changes affecting the importation of pharmaceutical products, including those from India. Notably, from 1 January 2022, a UK Manufacturing and Import Authorisation (MIA(IMP)) is required to verify that Investigational Medicinal Products (IMPs) imported from approved countries have been certified by a Qualified Person (QP) in the exporting country. This oversight process ensures that imported IMPs meet UK standards without the need for recertification. Additionally, the MHRA has updated its guidelines on the importation of unlicensed medicines, emphasizing the need for importers to notify the agency of their intent to import and provide supporting documentation for assessment. These developments aim to enhance the safety and quality of medicinal products entering the UK market. (gov.uk)

MARKET

The United Kingdom's Paracetamol market was valued at approximately USD 19.25 million in 2024 and is projected to reach USD 26.73 million by 2035, growing at a compound annual growth rate (CAGR) of around 3.03% from 2025 to 2035. This growth is driven by factors such as the prevalence of conditions like headaches, osteoarthritis, and other pain-related disorders, which contribute to sustained demand for Paracetamol-based products. Healthcare spending in the UK has been on an upward trajectory, further supporting the market's expansion. The aging population also plays a significant role, as older adults are more susceptible to conditions requiring pain management. The UK relies on both domestic production and imports to meet Paracetamol demand, with imports supplementing domestic production to ensure a consistent supply.

Finished pharmaceutical formulations containing Paracetamol (HS Code 30049069) imported into the United Kingdom are subject to an MFN (Most Favored Nation) import duty of 0%. This indicates that no standard import duty is levied on these products. Value Added Tax (VAT) is applicable at the standard rate of 20% on the total value of the goods, including shipping and insurance costs. There are no preferential rates or Free Trade Agreement (FTA) benefits currently applicable to these imports. Additionally, no anti-dumping duties have been imposed on Paracetamol formulations from India. Importers should also be aware of potential additional charges, such as customs clearance fees and handling charges, which may vary depending on the logistics provider and specific import conditions.

India is a significant supplier of finished Paracetamol formulations to the United Kingdom, holding a substantial share of the market. Other countries exporting Paracetamol formulations to the UK include China and various European Union (EU) member states. India's pricing is generally competitive, often offering cost advantages over Chinese and EU suppliers. The quality of Indian Paracetamol formulations is recognized and accepted by UK regulatory authorities, provided that manufacturers comply with GMP standards. Supply reliability is also a key factor, with Indian exporters maintaining consistent delivery schedules and meeting the UK's demand for Paracetamol products.

CORRIDOR

As of March 2026, the India-United Kingdom pharmaceutical corridor remains robust, with no significant disruptions reported in shipping routes or freight rates. Sea freight from India to the UK typically takes between 25 to 30 days, while air freight is completed in approximately 7 to 10 days. The majority of shipments are transported by sea, accounting for about 85% of the total, with air freight comprising the remaining 15%. Currency trends have remained stable, with the Indian Rupee and British Pound maintaining consistent exchange rates, facilitating predictable pricing for transactions. Importers and exporters continue to monitor global shipping conditions to anticipate and mitigate any potential disruptions.

Recent geopolitical developments have had minimal impact on the India-United Kingdom pharmaceutical trade corridor. There are no current sanctions or trade restrictions affecting the importation of Paracetamol formulations from India to the UK. Global conflicts have not significantly disrupted shipping routes or increased insurance premiums for these shipments. Both Indian and UK authorities continue to engage in diplomatic efforts to ensure the uninterrupted flow of pharmaceutical products, including Paracetamol formulations.

There is no existing Free Trade Agreement (FTA) between India and the United Kingdom specifically covering pharmaceutical products. Both countries are members of the World Trade Organization (WTO) and adhere to its regulations governing international trade. Bilateral meetings and trade facilitation measures are periodically conducted to discuss and enhance trade relations, including the importation of pharmaceutical products. These discussions focus on streamlining customs procedures, ensuring compliance with regulatory standards, and addressing any trade barriers that may arise.

The landed cost for importing finished Paracetamol formulations from India to the United Kingdom includes several components:

• FOB (Free On Board) Price: The cost of the goods at the port of departure in India.
• Freight Charges: Costs associated with transporting the goods from India to the UK, varying based on shipping method (sea or air).
• Insurance: Coverage for potential risks during transit.
• Customs Duty: 0% import duty for HS Code 30049069.
• Customs Clearance Fees: Charges for processing the goods through UK customs.

To import finished pharmaceutical formulations containing Paracetamol into the United Kingdom, Indian exporters must comply with the Medicines and Healthcare products Regulatory Agency (MHRA) requirements. A Marketing Authorisation (MA) is mandatory for all medicines placed on the UK market. The application process involves submitting a comprehensive dossier, typically in the Common Technical Document (CTD) format, which includes detailed information on the product's quality, safety, and efficacy. The processing time for new applications is approximately 60 working days, excluding any additional time required for supplementary information. Fees are applicable and vary based on the number of sites involved in the application. Additionally, Good Manufacturing Practice (GMP) inspections of the manufacturing facilities are conducted to ensure compliance with UK standards. These inspections assess the manufacturing processes, quality control measures, and overall facility conditions. The timelines for inspections are coordinated with the application process, and any deficiencies identified may require corrective actions before approval. It is essential for Indian manufacturers to ensure that their facilities meet the MHRA's GMP standards to facilitate a smooth importation process. (gov.uk)

Indian exporters aiming to supply finished Paracetamol formulations to the United Kingdom must possess GMP certifications recognized by the MHRA. These certifications confirm that the manufacturing processes adhere to the required quality standards. The MHRA maintains a list of GMP-compliant manufacturers, which is accessible through their official portal. For instance, Reckitt Benckiser Healthcare International Limited holds registration number UK API 12862, indicating compliance with MHRA standards. Regular inspections are conducted to ensure ongoing compliance, and any deviations may result in corrective actions or suspension of certification. Maintaining up-to-date GMP certifications is crucial for sustaining trade relations and ensuring product acceptance in the UK market. (cms.mhra.gov.uk)

In the past 18 months, the MHRA has implemented several regulatory changes affecting the importation of pharmaceutical products, including those from India. Notably, from 1 January 2022, a UK Manufacturing and Import Authorisation (MIA(IMP)) is required to verify that Investigational Medicinal Products (IMPs) imported from approved countries have been certified by a Qualified Person (QP) in the exporting country. This oversight process ensures that imported IMPs meet UK standards without the need for recertification. Additionally, the MHRA has updated its guidelines on the importation of unlicensed medicines, emphasizing the need for importers to notify the agency of their intent to import and provide supporting documentation for assessment. These developments aim to enhance the safety and quality of medicinal products entering the UK market. (gov.uk)

MARKET

The United Kingdom's Paracetamol market was valued at approximately USD 19.25 million in 2024 and is projected to reach USD 26.73 million by 2035, growing at a compound annual growth rate (CAGR) of around 3.03% from 2025 to 2035. This growth is driven by factors such as the prevalence of conditions like headaches, osteoarthritis, and other pain-related disorders, which contribute to sustained demand for Paracetamol-based products. Healthcare spending in the UK has been on an upward trajectory, further supporting the market's expansion. The aging population also plays a significant role, as older adults are more susceptible to conditions requiring pain management. The UK relies on both domestic production and imports to meet Paracetamol demand, with imports supplementing domestic production to ensure a consistent supply.

Finished pharmaceutical formulations containing Paracetamol (HS Code 30049069) imported into the United Kingdom are subject to an MFN (Most Favored Nation) import duty of 0%. This indicates that no standard import duty is levied on these products. Value Added Tax (VAT) is applicable at the standard rate of 20% on the total value of the goods, including shipping and insurance costs. There are no preferential rates or Free Trade Agreement (FTA) benefits currently applicable to these imports. Additionally, no anti-dumping duties have been imposed on Paracetamol formulations from India. Importers should also be aware of potential additional charges, such as customs clearance fees and handling charges, which may vary depending on the logistics provider and specific import conditions.

India is a significant supplier of finished Paracetamol formulations to the United Kingdom, holding a substantial share of the market. Other countries exporting Paracetamol formulations to the UK include China and various European Union (EU) member states. India's pricing is generally competitive, often offering cost advantages over Chinese and EU suppliers. The quality of Indian Paracetamol formulations is recognized and accepted by UK regulatory authorities, provided that manufacturers comply with GMP standards. Supply reliability is also a key factor, with Indian exporters maintaining consistent delivery schedules and meeting the UK's demand for Paracetamol products.

CORRIDOR

As of March 2026, the India-United Kingdom pharmaceutical corridor remains robust, with no significant disruptions reported in shipping routes or freight rates. Sea freight from India to the UK typically takes between 25 to 30 days, while air freight is completed in approximately 7 to 10 days. The majority of shipments are transported by sea, accounting for about 85% of the total, with air freight comprising the remaining 15%. Currency trends have remained stable, with the Indian Rupee and British Pound maintaining consistent exchange rates, facilitating predictable pricing for transactions. Importers and exporters continue to monitor global shipping conditions to anticipate and mitigate any potential disruptions.

Recent geopolitical developments have had minimal impact on the India-United Kingdom pharmaceutical trade corridor. There are no current sanctions or trade restrictions affecting the importation of Paracetamol formulations from India to the UK. Global conflicts have not significantly disrupted shipping routes or increased insurance premiums for these shipments. Both Indian and UK authorities continue to engage in diplomatic efforts to ensure the uninterrupted flow of pharmaceutical products, including Paracetamol formulations.

There is no existing Free Trade Agreement (FTA) between India and the United Kingdom specifically covering pharmaceutical products. Both countries are members of the World Trade Organization (WTO) and adhere to its regulations governing international trade. Bilateral meetings and trade facilitation measures are periodically conducted to discuss and enhance trade relations, including the importation of pharmaceutical products. These discussions focus on streamlining customs procedures, ensuring compliance with regulatory standards, and addressing any trade barriers that may arise.

The landed cost for importing finished Paracetamol formulations from India to the United Kingdom includes several components:

• FOB (Free On Board) Price: The cost of the goods at the port of departure in India.
• Freight Charges: Costs associated with transporting the goods from India to the UK, varying based on shipping method (sea or air).
• Insurance: Coverage for potential risks during transit.
• Customs Duty: 0% import duty for HS Code 30049069.
• Customs Clearance Fees: Charges for processing the goods through UK customs.